The University of Michigan Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 64 Trials 
74 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hussain, Maha Hadi A
PROfound, NCT02987543 / 2016-000300-28: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer ( Study)

Checkmark Quality of life data from PROfound trial in mCRPC
Feb 2022 - Feb 2022: Quality of life data from PROfound trial in mCRPC
Checkmark Acceptance of regulatory submission in China for prostate cancer (based on PROfound trial)
Jun 2021 - Jun 2021: Acceptance of regulatory submission in China for prostate cancer (based on PROfound trial)
Checkmark Approved for BRCAm mCRPC with distant metastasis based on PROfound trial
More
Completed
3
387
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, enzalutamide, XTANDI, abiraterone acetate, ZYTIGA
AstraZeneca, Merck Sharp & Dohme LLC, Foundation Medicine, Inc., Myriad Genetics, Inc.
Metastatic Castration-resistant Prostate Cancer
06/19
02/23
NCT04033432: sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
14
US
Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
Northwestern University, Vasgene Therapeutics, Inc, National Cancer Institute (NCI)
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Adenocarcinoma, Progressive Disease, Prostate Carcinoma Metastatic in the Bone, Prostate Carcinoma Metastatic in the Soft Tissue, PSA Progression, Stage IVB Prostate Cancer AJCC v8, Testosterone Less Than 50 ng/dL
02/21
06/22
NCT02452008: Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Active, not recruiting
2
60
US
Enzalutamide, XTANDI, LY2157299, TGF-β receptor inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Eli Lilly and Company
Prostate Cancer
05/25
05/26
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
Smith, David C
NCT04518410: ACTIV-2: A Study for Outpatients With COVID-19

Hourglass Jul 2022 - Dec 2022 : Data from ACTIV-2 trial for COVID-19
Hourglass May 2022 - Dec 2022 : Data from ACTIV-2 trial for the treatment of COVID-19
Checkmark Safety and efficacy data from ACTIV-2 P2/3 trial for the treatment for COVID-19
Jan 2022 - Jan 2022: Safety and efficacy data from ACTIV-2 P2/3 trial for the treatment for COVID-19
Checkmark Data from ACTIV-2 trial in combination with BRII-198 for COVID-19
More
Completed
2/3
4044
Canada, US, RoW
bamlanivimab 7000mg, LY3819253, BRII-196+BRII-198, AZD7442 (IV), AZD8895 + AZD1061, AZD7442 (IM), SNG001, Camostat, FOY-305, camostat mesilate, camostat mesylate, BMS-986414 + BMS-986413, C135-LS + C144-LS, SAB-185 (3,840 Units/kg), Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (Tc bovine-derived), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, REGN10933 + REGN10987, REGN-COV2, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
National Institute of Allergy and Infectious Diseases (NIAID), Eli Lilly and Company, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Brii Biosciences Limited, AstraZeneca, Sagent Pharmaceuticals, Synairgen Research Ltd., Bristol-Myers Squibb, SAb Biotherapeutics, Inc.
Coronavirus, Covid19
04/22
06/23
BOLD-HTN, NCT06343298: To Evaluate the Safety and Efficacy of MANP in Subjects with Difficult to Control/ Resistant Hypertension

Recruiting
2
132
US
MANP, Placebo Matched control
E-Star BioTech, LLC, Mayo Clinic, PPD DEVELOPMENT, LP
Difficult to Control Hypertension
09/25
12/25
NCT02555189: Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Completed
1/2
46
US
Enzalutamide, Xtandi, MDV3100, 915087-33-1, ASP9785, Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-, Ribociclib, LEE011, 1211441-98-3, 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, Kisqali, LEE-011, Laboratory Biomarker Analysis, Pharmacological Study, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Biopsy, BIOPSY_TYPE, Bx, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT SCAN, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI
Sidney Kimmel Cancer Center at Thomas Jefferson University, Novartis, Prostate Cancer Clinical Trials Consortium
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
12/22
09/23
Rewire, NCT04027075: Mindfulness Mobile App to Reduce Adolescent Substance Use

Completed
N/A
257
US
Qlarity app users
Oregon Research Behavioral Intervention Strategies, Inc.
Adolescent Drinking, Adolescent Problem Behavior
04/23
04/23
PeriGrief, NCT05318287: Walk With Me for Perinatal Grief

Completed
N/A
52
US
Walk with Me
Oregon Research Behavioral Intervention Strategies, Inc.
Grief, Traumatic Stress, Usability
09/23
09/23
NCT04633434: Evaluation Study of Talk Parenting Skills

Completed
N/A
98
US
The Talk Parenting Skill for Alexa
Oregon Research Behavioral Intervention Strategies, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Parenting Practices, Self Efficacy, Stress, Child Behavior, Emotional Adjustment, Sleep Problems, Parent-Child Relations
02/24
02/24
FamilyNet, NCT05535387: Integrated Smart Speaker Promoting Positive Parenting Among Caregivers of Youth With Challenging Behaviors

Completed
N/A
23
US
FamilyNet smart speaker/mobile application
Oregon Research Behavioral Intervention Strategies, Inc.
Oppositional Defiant Disorder, Conduct Disorder
12/24
12/24
PhatLife-II, NCT05339412: Technology-based Training Tool for PHAT Life

Completed
N/A
24
US
Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life
Oregon Research Behavioral Intervention Strategies, Inc., University of Illinois at Chicago
HIV Infection, Sexually Transmitted Infections, Implementation
11/24
12/24
TSFII, NCT04896229: Talk STEM Familia: Dual-Language

Completed
N/A
400
US
Talk STEM Familia Treatment Condition
Oregon Research Behavioral Intervention Strategies, Inc.
Vocabulary Acquisition
09/24
09/24
CoQuit, NCT05797155: A Mobile App Based Cognitive Dissonance Intervention for Smoking Cessation

Active, not recruiting
N/A
440
US
CoQuit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips, Tips for Smoking Cessation App
Oregon Research Behavioral Intervention Strategies, Inc.
Tobacco Use
03/25
03/25
NCT06099457: SIBTime Phase II: Web Application for Typically Developing Siblings

Recruiting
N/A
160
US
SIB-Time web-application tool
Oregon Research Behavioral Intervention Strategies, Inc., National Institute on Minority Health and Health Disparities (NIMHD)
Early Life Stress
09/25
01/26
BR2S-II, NCT05321719: Multi-Media Parent-based Intervention to Promote Dental Hygiene Among Young Children: BeReady2Smile II

Completed
N/A
228
NA
Comparison Condition, BeReady2Smile video only, BeReady2Smile video and BeReady2Smile app completely self-guided, "Complete" BeReady2Smile video and BeReady2Smile app guided by a Coach
Oregon Research Behavioral Intervention Strategies, Inc.
Plaque
04/24
04/24
NCT04457154: Pediatric Post-Approval Registry

Recruiting
N/A
60
US
Inspire Upper Airway Stimulation System
Inspire Medical Systems, Inc.
Obstructive Sleep Apnea
12/27
04/28
NCT05603728: Exactech Shoulder Post Market Clinical Follow-up Study

Recruiting
N/A
20000
Europe, US
Exactech
Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
12/30
09/31
Gadgeel, Shirish M
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC
Active, not recruiting
2
68
US, RoW
Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®
Effector Therapeutics, Medpace, Inc., ICON plc
Non-small Cell Lung Cancer
10/24
12/24
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
CA239-0010, NCT05609578: Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Recruiting
2
90
Europe, US, RoW
Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin
Mirati Therapeutics Inc.
Advanced NSCLC, Metastatic Lung Cancer
06/26
12/26
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
NCT04442126 / 2021-000441-41: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Terminated
1/2
52
Europe, US, RoW
NM21-1480
Numab Therapeutics AG
Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
02/24
02/24
NCT05023486: NP-G2-044 As Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1/2
140
US
NP-G2-044 Monotherapy, Anti-PD-1 Therapy, NP-G2-044 Combination therapy
Novita Pharmaceuticals, Inc.
Advanced or Metastatic Solid Tumor Malignancies
09/25
09/25
(MARGARET), NCT04683250: Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Recruiting
1/2
202
Japan, US
TAS0953/HM06
Helsinn Healthcare SA, ICON Clinical Research
RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
03/25
09/25
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Recruiting
1/2
237
US
REGN5093-M114, Cemiplimab
Regeneron Pharmaceuticals
Advanced NSCLC
02/30
02/30
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
SHIELD-1, NCT03993873: Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Active, not recruiting
1
95
Europe, US, RoW
elzovantinib (TPX-0022)
Turning Point Therapeutics, Inc.
Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
01/24
03/26
HEROEX-1, NCT06521554: A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC

Recruiting
1
120
US
NVL-330
Nuvalent Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
03/26
03/26
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
Smith, Ellen L
EPIPHANY, NCT03997981: Chemotherapy Induced Peripheral Neuropathy Natural History Study

Recruiting
N/A
200
US
Disarm Therapeutics, Eli Lilly and Company
Chemotherapy-induced Peripheral Neuropathy
03/24
04/24
Magenau, John
Precision-T (PhIII component), NCT05316701: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
3
174
US
Orca-T, Standard-of-Care, SOC
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
04/25
04/27
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Previously treated CAR-T patients
Novartis Pharmaceuticals, University of Pennsylvania
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
02/36
02/36
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
12/24
11/26
Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
1
255
US
Orca-T
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
07/24
07/26
Mody, Rajen
NCT04724369: Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Completed
3
43
US
18F-MFBG, meta-fluorobenzylguanidine, IRP101
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), New Approaches to Neuroblastoma Therapy Consortium, Memorial Sloan Kettering Cancer Center
Neuroblastoma
02/24
02/24
NCT06450041: NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Recruiting
2
62
US
Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan, Dinutuximab, Unituxin, GM-CSF, Sargramostim
New Approaches to Neuroblastoma Therapy Consortium, Nationwide Children's Hospital, United Therapeutics, Children's Neuroblastoma Cancer Fund
Neuroblastoma
12/28
12/38
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Active, not recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
T2017-002, NCT03817320 / 2019-001947-28: PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting
1/2
31
US, RoW
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Therapeutic Advances in Childhood Leukemia Consortium, Takeda, Children's Hospital Los Angeles
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
12/24
06/25
NCT03332667: MIBG With Dinutuximab +/- Vorinostat

Active, not recruiting
1
45
US
131I-MIBG, 131I-Metaiodobenzylguanidine, Iobenguane sulfate, m-Iodobenzylguanidine sulfate, MIBG, Dinutuximab, Chimeric Monoclonal Antibody 14.18, MAB Ch 14.18, Unituxin, Ch14.18, Vorinostat, Zolina, Sargramostim, Potassium Iodide
New Approaches to Neuroblastoma Therapy Consortium, United Therapeutics
Neuroblastoma
02/24
06/25
NCT03107988: NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Active, not recruiting
1
65
Europe, Canada, US
Lorlatinib, PF06463922, Cyclophosphamide, Cytoxan, Topotecan, SKF-104864,Hycamtin®, Filgrastim/pegfilgrastim
New Approaches to Neuroblastoma Therapy Consortium, Pfizer, University of Southern California, Solving Kids' Cancer US/EU, Children's Neuroblastoma Cancer Foundation, The Band of Parents, The Evan Foundation, Wade's Army, Ronan Thompson Foundation, The Catherine Elizabeth Blair Memorial Foundation, Cookies for Kids' Cancer
Neuroblastoma
12/24
12/25
NCT04239092: 9-ING-41 in Pediatric Patients with Refractory Malignancies.

Recruiting
1
68
US
9-ING-41, 9-ING-41 COMPOUND, Irinotecan, CPT-11, Temozolomide, Temodar, Cyclophosphamide, Cyclophosphamide IV, Topotecan, Topotecan IV
Actuate Therapeutics Inc.
Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
12/24
12/24
NCT06247787: A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recruiting
1
36
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Echocardiography, EC, Fludarabine, Fluradosa, Hydrocortisone Sodium Succinate, (11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt, A-Hydrocort, Buccalsone, Corlan, Cortisol Sodium Succinate, Cortop, Efcortelan, Emergent-EZ, Flebocortid, Hidroc Clora, Hycorace, Hydro-Adreson, Hydrocort, Hydrocortisone 21-Sodium Succinate, Hydrocortisone Na Succinate, Kinogen, Nordicort, Nositrol, Sinsurrene, Sodium hydrocortisone succinate, Solu-Cortef, Solu-Glyc, Imetelstat, GRN 163L, GRN-163L, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Lumbar Puncture, LP, Spinal Tap, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039
Children's Oncology Group, Geron Corporation, National Cancer Institute (NCI)
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
06/26
06/26
Mierzwa, Michelle
NCT03829722: Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

Completed
2
26
US
Nivolumab, Opdivo, BMS-936558, MDX1106, ONO-4538, Carboplatin, Paraplatin, Paclitaxel, Taxol, Radiation Therapy
University of Michigan Rogel Cancer Center, Bristol-Myers Squibb
Oropharynx Squamous Cell Carcinoma
06/24
06/24
Spratt, Daniel
ASCLEPIuS, NCT04194554: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Active, not recruiting
1/2
102
US
Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT), Ultra-hypofractionated radiotherapy
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC
Prostate Cancer
11/26
05/27
NCT04396808: Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

Recruiting
N/A
900
US
Decipher, Decipher Prostate Cancer Classifier, Prolaris, Prolaris Prostate Cancer Test, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score), askMUSIC score
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), Myrexis Inc., Veracyte, Inc., MDx Health
Prostate Cancer
07/25
07/25
Burke, Patrick
STIMULUS MDS-US, NCT04878432: : Sabatolimab Added to HMA in Higher Risk MDS

Completed
2
39
US
MBG453, sabatolimab, Azacitidine, Decitabine, INQOVI (oral decitabine)
Novartis Pharmaceuticals
Myelodysplastic Syndrome (MDS)
09/23
09/24
NCT04845035: Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Withdrawn
2
23
US
Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy, Methotrexate and Cytarabine
University of Michigan Rogel Cancer Center, Takeda
Acute Lymphoblastic Leukemia
01/26
01/29
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
Welling, Theodore
BASECAMP-1, NCT04981119: Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Recruiting
N/A
200
US
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
A2 Biotherapeutics Inc., Tempus AI
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer
12/25
12/26
Line, Cancer Answer
NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Terminated
2
47
US
Ulixertinib, BVD-523, BVD523, Hydroxychloroquine
BioMed Valley Discoveries, Inc
Tumor, Solid, Gastrointestinal Cancer
05/24
07/24
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Recruiting
2
123
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
VBP101, NCT04849910: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Recruiting
1/2
24
Canada, US
VOR33, Mylotarg, gemtuzumab ozogamicin
Vor Biopharma
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
02/25
01/27
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
COMMANDER-001, NCT05357898: Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated
1/2
20
US
SQZ-eAPC-HPV, Pembrolizumab
SQZ Biotechnologies
Adult Solid Tumor
11/23
11/23
KYANITE-1, NCT06228326: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Recruiting
1/2
140
US
KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy
Krystal Biotech, Inc.
Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)
02/27
02/27
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
12/24
11/26
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
NCT05440708: A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Recruiting
1/2
166
US
TTI-101, Pembrolizumab, Keytruda®, Atezolizumab, Tecentriq®, Bevacizumab, Avastin®
Tvardi Therapeutics, Incorporated
Hepatocellular Carcinoma
03/25
03/25
OPAL-1, NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
140
US
KB707, Opdualag
Krystal Biotech, Inc.
Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
07/26
07/26
NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting
1/2
300
Canada, US
LCB84, Anti-PD-1 monoclonal antibody
LigaChem Biosciences, Inc., AntibodyChem Biosciences, Inc.
Advanced Solid Tumors
01/27
05/27
TPST-1495-001, NCT04344795: Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Active, not recruiting
1
175
US
TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab, Keytruda
Tempest Therapeutics
Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
11/24
12/24
CDR404-001, NCT06402201: First in Human Study of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

Recruiting
1
42
Europe, US
CDR404
CDR-Life AG
Select Advanced Solid Tumors
06/26
12/27
STK-009-101, NCT05665062: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Recruiting
1
36
US
SYNCAR-001, STK-009, Cyclophosphamide, Fludarabine
Synthekine
CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
06/26
11/26
CPO-100-US-101, NCT04931823: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Active, not recruiting
1
126
US
CPO-100, DTX-HSA
Conjupro Biotherapeutics, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Solid Tumor
03/25
03/25
NCT05973487: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Recruiting
1
100
US
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
12/26
12/26
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT04797390: A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema

Active, not recruiting
N/A
250
US
Advanced Pneumatic Compression Device (APCD), Flexitouch, Flexitouch Plus, Usual Care, Complete Decongestive Therapy (CDT), Manual Lymphatic Drainage (MLD)
Tactile Medical, Vanderbilt University Medical Center
Lymphedema, Lymphedema of Face, Lymphedema, Secondary, Lymphedema Due to Radiation, Lymphedema; Surgical
01/25
01/25
NCT05812027: A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting
N/A
650
US
Tumor and HLA Profiling
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
01/26
01/27
NCT05309733: A Long-term Follow-up Study of Patients Who Received VOR33

Recruiting
N/A
36
Canada, US
VOR33
Vor Biopharma
Leukemia, Myeloid, Acute
01/40
01/40
Kraft, Shawna
No trials found

Download Options